• 1. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 2. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569

Introduction to 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine (CAS No. 32900-36-0)

1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine, identified by the Chemical Abstracts Service registry number CAS No. 32900-36-0, is a significant compound in the field of pharmaceutical chemistry. This molecule belongs to the benzodiazepine class, which is well-documented for its pharmacological properties, particularly in the modulation of central nervous system activity. The structural framework of 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine incorporates a seven-membered lactam ring fused with a benzene ring, a configuration that is characteristic of many benzodiazepine derivatives. The presence of a methyl group at the 1-position and a tetrahydropyridine moiety at the 2-, 3-, 4-, and 5-positions contributes to its unique pharmacokinetic and pharmacodynamic profile.

The compound has garnered attention in recent years due to its potential therapeutic applications. Benzodiazepines are widely recognized for their anxiolytic, sedative, muscle relaxant, and anticonvulsant effects, which are mediated through their interaction with the gamma-aminobutyric acid (GABA) receptor complex. Specifically, 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine exhibits selectivity that may make it a valuable candidate for treating conditions such as anxiety disorders and insomnia. Its ability to enhance GABAergic neurotransmission suggests that it could offer a more targeted approach compared to broader-spectrum benzodiazepines.

Recent advancements in pharmacological research have highlighted the importance of structure-activity relationships (SAR) in optimizing benzodiazepine derivatives. The modification of the tetrahydropyridine ring in 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine appears to influence its binding affinity and duration of action. Studies have demonstrated that subtle changes in this region can significantly alter the compound's efficacy and side effect profile. For instance, the introduction of substituents that enhance metabolic stability can prolong the therapeutic window while minimizing residual effects.

One of the most compelling aspects of 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine is its potential for developing novel therapeutic strategies. Emerging research indicates that this compound may have applications beyond traditional benzodiazepine indications. For example, preclinical studies have suggested that it could modulate neuroinflammatory pathways associated with neurological disorders such as Alzheimer's disease and Parkinson's disease. The ability of 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine to interact with specific GABA receptor subtypes may provide a mechanism for reducing neuroinflammation without inducing excessive sedation.

The synthesis of 1-Methyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. The formation of the lactam ring is a critical step in its synthesis and necessitates careful optimization to ensure high yield and purity. Advances in catalytic methods have enabled more efficient routes to this compound without compromising on quality. These improvements are essential for scaling up production while maintaining cost-effectiveness.

In terms of pharmacokinetics, 1-Methyl-2,3,4,5-tetrahydro-1H-1H-benzodiazepine exhibits properties that make it an attractive candidate for clinical development. Its moderate lipophilicity allows for good blood-brain barrier penetration but also minimizes systemic side effects associated with highly lipophilic benzodiazepines. Additionally, its metabolic profile suggests a favorable half-life distribution, making it suitable for both acute and chronic treatment regimens.

The safety profile of CAS No. 32900-36 -0 is another area where recent research has provided valuable insights. Traditional benzodiazepines are known for their potential for dependence and tolerance, but modifications such as those seen in tetrahydropyridine derivatives may offer improved safety profiles.* Long-term studies are needed to fully understand these implications, but preliminary findings are promising.

The regulatory landscape surrounding benzodiazepine derivatives continues to evolve, with increasing emphasis on stringent controls due to misuse concerns.* However, compounds like CAS No 32900 -36 -0 are positioned as potential alternatives due to their tailored pharmacological properties.* This could pave the way for new treatment paradigms while addressing existing challenges associated with benzodiazepines.

Future directions in research on CAS No 32900 -36 -0 include exploring its potential as an adjunct therapy in combination with other medications.* For example, its anxiolytic effects could complement treatments for depression or chronic pain syndromes.* Additionally, investigating its role in cognitive enhancement or memory modulation remains an exciting possibility given its GABAergic mechanisms.

In conclusion, CAS No 32900 -36 -0 represents a significant advancement in pharmaceutical chemistry.* Its unique structural features,* coupled with promising preclinical data,* position it as a compelling candidate for further development.* As research progresses,* we can anticipate new insights into its therapeutic potential* and how it may shape future treatments across multiple medical disciplines.*

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)